FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922763339> ?p ?o ?g. }

• W2922763339 endingPage "14" @default.
• W2922763339 startingPage "8" @default.
• W2922763339 abstract "To investigate the role of 18F-FDG positron emission tomography/computed tomography (PET/CT) in detection of recurrence in ovarian cancer patients with increased CA-125 levels.Fifty-two patients (30-80 years old, mean: 58.5±10.6 years) who had been histopathologically diagnosed with ovarian cancer, underwent 18F-FDG PET/CT imaging for re-staging due to elevation of CA-125 levels were included in this retrospective study. 18F-FDG PET/CT findings were compared with histopathological, radiological and clinical follow-up results.CA-125 levels ranged between 35.2-2740 U/mL (N: 0-35 U/mL). Recurrent disease was detected in 45 of 52 patients on PET/CT imaging. There were three false negative and one false positive result. In addition to abdominal and pelvic lesions, 14 distant metastatic lesions (brain, lung, liver and bone metastasis) were identified correctly on PET/CT imaging. Sensitivity, specificity, positive and negative predictive value and accuracy of 18F-FDG PET/CT were calculated as 94%, 75%, 98%, 50% and 96%, respectively.18F-FDG PET/CT is a useful imaging method that can be used in detection of ovarian cancer recurrence in patients with elevated CA-125 levels. Since this modality offers whole body imaging, distant metastases could be detected in addition to abdominal and pelvic lesions thus contributing to patient management.Bu çalışmanın amacı, serum CA-125 düzeylerinde artış olan over kanserli hastalarda rekürrens saptamada 18F-FDG pozitron emisyon tomografi/bilgisayarlı tomografinin (PET/BT) rolünü araştırmaktır.Bu retrospektif çalışmaya histopatolojik olarak over kanseri tanısı almış, CA-125 düzeylerinde artış nedeniyle yeniden evreleme amacıyla 18F-FDG PET/BT yapılan 52 hasta (30-80 yaş, ortalama: 58,5±10,6 yaş) dahil edildi. 18F-FDG PET/BT bulguları histopatolojik bulgular veya radyolojik ve klinik izlem sonuçlarıyla karşılaştırıldıCA-125 düzeyleri 35,2-2740 U/mL (N: 0-35 U/mL) aralığındaydı. PET/BT görüntülerinde rekürren hastalık 52 hastanın 45’inde gösterildi. Üç yanlış negatif, bir yanlış pozitif sonuç elde edildi. Abdominal ve pelvik lezyonlara ilave olarak 14 uzak metastaz (beyin, akciğer, karaciğer ve kemik metastazı) PET/BT ile doğru olarak gösterildi. Duyarlılık, özgüllük, pozitif ve negatif öngörü değeri ve doğruluk sırasıyla %94, %75, %98, %50 ve %96 idi.18F-FDG PET/BT, serum CA-125 düzeylerinde artış olan over kanserli hastalarda rekürrens saptamada kullanılabilecek yararlı bir yöntemdir. Tüm vücut görüntüleme yöntemi olması nedeniyle abdominal ve pelvik lezyonların yanında uzak metastazları da saptayarak bu hastaların izlemine katkıda bulunabilir." @default.
• W2922763339 created "2019-04-01" @default.
• W2922763339 creator A5007087484 @default.
• W2922763339 creator A5009566332 @default.
• W2922763339 creator A5028507258 @default.
• W2922763339 creator A5064782512 @default.
• W2922763339 date "2019-02-01" @default.
• W2922763339 modified "2023-10-13" @default.
• W2922763339 title "The Role of ¹⁸F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels" @default.
• W2922763339 cites W1594695427 @default.
• W2922763339 cites W1969807640 @default.
• W2922763339 cites W1987546620 @default.
• W2922763339 cites W1988773293 @default.
• W2922763339 cites W1993579733 @default.
• W2922763339 cites W1998258610 @default.
• W2922763339 cites W2009428431 @default.
• W2922763339 cites W2009985974 @default.
• W2922763339 cites W2019259766 @default.
• W2922763339 cites W2045801335 @default.
• W2922763339 cites W2059947530 @default.
• W2922763339 cites W2077438431 @default.
• W2922763339 cites W2092160355 @default.
• W2922763339 cites W2097718374 @default.
• W2922763339 cites W2107856698 @default.
• W2922763339 cites W2128168267 @default.
• W2922763339 cites W2132844741 @default.
• W2922763339 cites W2147044943 @default.
• W2922763339 cites W2162811770 @default.
• W2922763339 cites W2335600798 @default.
• W2922763339 cites W2413060135 @default.
• W2922763339 cites W2772815803 @default.
• W2922763339 cites W60018830 @default.
• W2922763339 doi "https://doi.org/10.4274/mirt.galenos.2018.00710" @default.
• W2922763339 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6455098" @default.
• W2922763339 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30942056" @default.
• W2922763339 hasPublicationYear "2019" @default.
• W2922763339 type Work @default.
• W2922763339 sameAs 2922763339 @default.
• W2922763339 citedByCount "10" @default.
• W2922763339 countsByYear W29227633392020 @default.
• W2922763339 countsByYear W29227633392021 @default.
• W2922763339 countsByYear W29227633392022 @default.
• W2922763339 countsByYear W29227633392023 @default.
• W2922763339 crossrefType "journal-article" @default.
• W2922763339 hasAuthorship W2922763339A5007087484 @default.
• W2922763339 hasAuthorship W2922763339A5009566332 @default.
• W2922763339 hasAuthorship W2922763339A5028507258 @default.
• W2922763339 hasAuthorship W2922763339A5064782512 @default.
• W2922763339 hasBestOaLocation W29227633391 @default.
• W2922763339 hasConcept C121608353 @default.
• W2922763339 hasConcept C126322002 @default.
• W2922763339 hasConcept C126838900 @default.
• W2922763339 hasConcept C142724271 @default.
• W2922763339 hasConcept C2775842073 @default.
• W2922763339 hasConcept C2776256026 @default.
• W2922763339 hasConcept C2779013556 @default.
• W2922763339 hasConcept C2780427987 @default.
• W2922763339 hasConcept C2989005 @default.
• W2922763339 hasConcept C71924100 @default.
• W2922763339 hasConceptScore W2922763339C121608353 @default.
• W2922763339 hasConceptScore W2922763339C126322002 @default.
• W2922763339 hasConceptScore W2922763339C126838900 @default.
• W2922763339 hasConceptScore W2922763339C142724271 @default.
• W2922763339 hasConceptScore W2922763339C2775842073 @default.
• W2922763339 hasConceptScore W2922763339C2776256026 @default.
• W2922763339 hasConceptScore W2922763339C2779013556 @default.
• W2922763339 hasConceptScore W2922763339C2780427987 @default.
• W2922763339 hasConceptScore W2922763339C2989005 @default.
• W2922763339 hasConceptScore W2922763339C71924100 @default.
• W2922763339 hasIssue "1" @default.
• W2922763339 hasLocation W29227633391 @default.
• W2922763339 hasLocation W29227633392 @default.
• W2922763339 hasLocation W29227633393 @default.
• W2922763339 hasLocation W29227633394 @default.
• W2922763339 hasOpenAccess W2922763339 @default.
• W2922763339 hasPrimaryLocation W29227633391 @default.
• W2922763339 hasRelatedWork W2017484494 @default.
• W2922763339 hasRelatedWork W2056064246 @default.
• W2922763339 hasRelatedWork W2064573700 @default.
• W2922763339 hasRelatedWork W2169394819 @default.
• W2922763339 hasRelatedWork W2554284703 @default.
• W2922763339 hasRelatedWork W2967366602 @default.
• W2922763339 hasRelatedWork W2981696006 @default.
• W2922763339 hasRelatedWork W3047265282 @default.
• W2922763339 hasRelatedWork W4211208004 @default.
• W2922763339 hasRelatedWork W567261565 @default.
• W2922763339 hasVolume "28" @default.
• W2922763339 isParatext "false" @default.
• W2922763339 isRetracted "false" @default.
• W2922763339 magId "2922763339" @default.
• W2922763339 workType "article" @default.